Cancer Research

Across the South East region, GLH staff work with oncology and clinical trials teams to assess whether patients are eligible for various genomics related cancer studies. For patients who have had genomic testing through the GLH as part of their cancer care, where appropriate, they will be identified for suitable clinical trials via our Genomic Tumour Advisory Board (GTAB) meetings and this will then be discussed with their oncologist.

For more information on cancer research within Guy’s and St Thomas’ NHS Foundation Trust and to contact the cancer research team, please visit the Guy’s Cancer Research webpage.

Examples of ongoing trials

Below are a few examples of the current early phase and late phase trails that are running in the region:

Main aims:

The ARROW clinical trial will test an investigational drug called pralsetinib (formerly known as BLU-667) in people who have RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or another solid tumor that has a RET fusion or mutation. It is a phase 1/2 trial designed to test the safety and the initial clinical activity of pralsetinib.

 

Inclusion criteria:

  • At least 18 years of age
  • Are not eligible for surgery and have exhausted all standard therapy options
  • Have non-small cell lung cancer (NSCLC) with a known RET fusion or mutation OR
  • Have medullary thyroid cancer (MTC) - a known RET alteration is not required OR
  • Have another solid tumor with a known RET fusion or mutation.

 

Closing date: February 2024

 

Link to further information

Main aims:

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.

 

Inclusion criteria:

  • At least 18 years of age
  • Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1 that are considered nonamenable to surgery or other curative treatments or procedures
  • Willingness to undergo a tumor biopsy to obtain tumor tissue
  • Must have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to or ineligible for standard treatment.

 

Closing date: 12/08/2021

 

Link to further information

Main aims:

To assess the antitumor activity and safety of dostarlimab for patients with deficient mismatch repair endometrial cancer.

 

Inclusion criteria:

  • At least 18 years of age
  • Patients with deficient mismatch mutation repair endometrial cancer.

 

Closing date: 30/11/2023

 

Link to further information

Main aims:

The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer.

 

Inclusion criteria:

  • At least 16 years of age
  • Patients with a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT) OR
  • Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.

 

Closing date: 31/03/2022

 

Link to further information

Main aims:

The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinations.

 

Inclusion criteria:

  • At least 18 years of age
  • Patients with non small cell lung cancer that is either squamous cell carcinoma or adenocarcinoma
  • Histological or cytologically confirmed NSCLC stage III (not suitable for radical radiotherapy or surgery) or stage IV cancer
  • Where one or more standard lines of treatment have failed and the cancer has continued to grow.

 

Closing date: September 2021

 

Link to further information

Further information

The Experimental Cancer Medicine Centre (ECMC) Network
Cancer Research UK - Find a Clinical Trial
NIHR UK Clinical Trials Gateway
The UK Clinical Trials Gateway

South East Genomics

Welcome to our new home

We have recently changed our name from the NHS London South Genomic Laboratory Hub to the NHS South East Genomic Laboratory HubWe think it better reflects the region we cover!

Hello! Welcome to the South East GLH website. The site is not fully supported in older versions of Internet Explorer. To get the best experience, we recommend that you use Google Chrome or Firefox to browse the site.

With any Whole Genome Sequencing (WGS) test ordered, a Record of Discussion (RoD) form will also need to be submitted. This document is to record the patient’s consent for genomic testing and their choice on taking part in research. Guidance on the patient choice conversation can be found here
 
This RoD form will be available for clinicians to download from this webpage. Once completed with the patient, it can be send to the lab with the corresponding test order form and sample.
Tests available to order will be listed in the National Genomic Test Directory. A test order form will soon be made available for clinicians on this webpage to download and complete. This form will include the address of the laboratory that the appropriate sample and completed form needs to be sent to.
 
Until the new Genomic Laboratory Service goes live, please continue to follow existing test order processes.
 
Later this year, the online test ordering tool for Whole Genome Sequencing will be integrated into the National Genomics Informatics System (NGIS) and clinicians will be able to search or filter to find a clinical indication, confirm eligibility criteria and start the test request process for their patient.